Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ESPR
- Price
- 3.17
- Stock movement up
- +0.19 (6.38%)
- Company name
- Esperion Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 751.51M
- Ent value
- 1.47B
- Price/Sales
- 2.47
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 105.67
- PEG
- -
- EPS growth
- -40.11%
- 1 year return (CAGR)
- 47.44%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ESPR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.47 |
| Price to Book | - |
| EV to Sales | 4.85 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 237.07M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 303.80M |
| Gross profit (TTM) | 162.67M |
| Operating income (TTM) | -29.38M |
| Net income (TTM) | -105.83M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | 0.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 53.54% |
| Operating margin (TTM) | -9.67% |
| Profit margin (TTM) | -34.84% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 92.45M |
| Net receivables | 118.98M |
| Total current assets | 360.46M |
| Goodwill | 0.00 |
| Intangible assets | 56.00K |
| Property, plant and equipment | 3.50M |
| Total assets | 364.02M |
| Accounts payable | 77.51M |
| Short/Current long term debt | 600.99M |
| Total current liabilities | 359.03M |
| Total liabilities | 815.38M |
| Shareholder's equity | -451.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -93.29M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -93.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -29.07% |
| Return on Invested Capital | 209.54% |
| Cash Return on Invested Capital | 184.70% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.98 |
| Daily high | 3.21 |
| Daily low | 2.97 |
| Daily Volume | 7.14M |
| All-time high | 115.30 |
| 1y analyst estimate | 6.50 |
| Beta | 1.01 |
| EPS (TTM) | -0.53 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 24 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ESPR | S&P500 | |
| Current price drop from All-time high | -97.25% | -0.89% |
| Highest price drop | -99.37% | -19.00% |
| Date of highest drop | 14 May 2025 | 8 Apr 2025 |
| Avg drop from high | -98.14% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
751.51M
Marketcap category
Small-cap
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Employees
304
Website
Investor relations
-
SEC filings
CEO
Tim M. Mayleben
Country
USA
City
Ann Arbor
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page